Age is in the eye of the beholder: distinguishing molecular signatures in early-onset pancreatic adenocarcinomas

Research output: Contribution to journalArticlepeer-review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is more prevalent in older patients, but early-onset cases (<55 years) may be a distinct genetic subpopulation. Differential expression of CDKN2A and transcription factor FOXC2 were found in early-onset cases. This finding opens the door to investigating additional features that distinguish PDAC tumors in this age group.

Original languageEnglish (US)
Pages (from-to)8-10
Number of pages3
JournalClinical Cancer Research
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2021

Bibliographical note

Funding Information:
E. Lou reports research grants from the American Association for Cancer Research (2019 AACR-Novocure Tumor-Treating Fields Research Grant) and the Minnesota Ovarian Cancer Alliance; honorarium and travel expenses for a research talk at GlaxoSmithKline (2016); honoraria and travel expenses for lab-based research talks, and equipment for laboratory-based research from Novocure (2018–20); consultant, Nomocan Pharmaceuticals (unpaid); scientific advisory board member, Minnetronix, LLC (2018–present; unpaid); consultant and speaker honorarium, Boston Scientific US (2019); institutional principal investigator for clinical trials sponsored by Celgene, Novocure, Intima Biosciences, and the NCI; and University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (unpaid).

Publisher Copyright:
© 2020 American Association for Cancer Research.

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Comment

Fingerprint

Dive into the research topics of 'Age is in the eye of the beholder: distinguishing molecular signatures in early-onset pancreatic adenocarcinomas'. Together they form a unique fingerprint.

Cite this